BioSpace News Archive

NervGen Pharma Corp., a clinical stage biotech company dedicated to developing innovative solutions for the repair of nervous system damage, today announced it has been awarded up to US$1.5 million in US Department of Defense (DoD) funding from the Military Operational Medicine Research Program to evaluate NervGen’s NVG-291-R as a therapeutic to enable accelerated and enhanced restoration of function following peripheral nerve injury.

Derm-Biome Pharmaceuticals, Inc has initiated a program aimed at advancing its topical treatments for precancerous skin conditions such as actinic keratosis and non-melanoma skin cancers such as squamous cell carcinoma through to the clinic.

Collaboration brings together Avectas’ breakthrough cell engineering technology and Inceptor Bio’s CAR-T platform

SiSaf Ltd, an RNA delivery and therapeutics company, announces that it is initiating the U.S. FDA Regulatory process to obtain an Orphan Drug Designation for SIS-101-ADO, a siRNA therapeutic for patients with Autosomal Dominant Osteopetrosis Type 2 (ADO2), a rare genetic skeletal disorder.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it has received emergency use authorization from the U.S. Food and Drug Administration for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children and adolescents 6 to 17 years of age.

PDS Biotechnology Corporation announced it will host a Head and Neck Cancer Key Opinion Leader Roundtable for analysts, investors, and the scientific community from 8:30 – 9:30 AM ET on Wednesday, October 26, 2022.

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief Medical Officer (CMO).

Neurelis, Inc., a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need, announced it will present an analysis of a Phase 3 safety study of VALTOCO® CIV at the 2022 Annual Meeting of the Academy of Managed Care Pharmacy, Oct. 14 to 22, in National Harbor, MD.

Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to SARS-CoV-2 in a peer-reviewed research paper in the Journal of Theoretical Biology.

NeuroLogica Corp., a subsidiary of Samsung Electronics Co. Ltd., announced today that its state-of-the-art Elite Mobile Computed Tomography (CT) systems have received the European Union (EU) CE marking via compliance with the new EU Medical Device Regulation (MDR 2017/745).